Xalkori FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved August 26, 2011)
Brand name: Xalkori
Generic name: crizotinib
Dosage form: Capsules
Company: Pfizer Inc.
Treatment for: Non-Small Cell Lung Cancer; Anaplastic Large Cell Lymphoma
Xalkori (crizotinib) is an oral anaplastic lymphoma kinase (ALK) inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive or ROS1-positive, and for the the treatment of pediatric patients and young adults 1 year of age and older with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
Development Timeline for Xalkori
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.